We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas (CHIRACIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02364089
Recruitment Status : Active, not recruiting
First Posted : February 16, 2015
Last Update Posted : June 9, 2021
Information provided by (Responsible Party):
University Hospital, Bordeaux

Brief Summary:
The general objective is to evaluate the consequences of surgical removal of SCSI on hypertension and cardiovascular risk factors in order to determine on an evidence-based basis if surgical excision of SCSI is preferable to an intensive medical regimen in patients with hypertension.

Condition or disease Intervention/treatment Phase
Adrenal Incidentalomas Procedure: Laparoscopic surgical removal of the adrenal tumor Drug: Standardized medical treatment of hypertension by SAHR Not Applicable

Detailed Description:

Adrenal incidentalomas are unsuspected adrenal masses found during abdominal imaging. With the widespread use of computed tomography and MRI, adrenal incidentalomas are found in approximately 2% of patients. In an endocrinology setting, the majority of these masses are benign adenomas of the adrenal cortex. Approximately 10% of these adenomas display little excess of cortisol secretion associated to some degree of secretory autonomy but that are insufficient to generate overt Cushing's syndrome ("Subclinical Secreting Cortisol incidentalomas" or SCSI). However, hypertension and to a lesser degree obesity and impaired glucose tolerance are very frequent amongst patients with SCSI. The hypothesis that the mild hypercortisolism associated with SCSI is responsible for these clinical consequences is substantiated by few studies describing improvement after resection of SCSI. However, these studies were retrospective, uncontrolled and suffered from imprecision and numerous methodological bias. Thus, whether surgery is more beneficial than medical treatment is currently unknown and there is no consensus on the appropriate treatment for SCSI.

Patient selection Run-In period. Discontinuation of previous antihypertensive treatments and prescription of a standardized anti-hypertensive drug regimen (SAHR). Monthly Blood Pressure (BP) measurement using home BP monitoring. The duration of the Run-In periods will be ≤ 6 months and will end when BP will be controlled with the SAHR at two consecutive visits.

End of RI Second endocrine assessment for eligibility Randomization (Ra): 24h Ambulatory BP measurement, anthropometric and metabolic evaluation. Quality of life and cognition questionnaires. Randomization in 2 groups : Gr 1 Treatment group : Surgery followed by intensive medical care ; Gr 2 : Control Group : intensive medical care only.

Ra + 1Mo: Surgery in Group 1 Ra + 2.5 Mo to Ra + 13 Mo: 6 weeks interval follow-up Evaluation of home BP monitoring and adaptation of the SAHR. A step by step reduction of the SAHR will be attempted in the two patient groups at Ra+2.5Mo. A second attempt will systematically be performed in both groups at Ra+8.5 Medical evaluation of associated metabolic conditions (obesity, diabetes, dyslipidemia) and adaptation of treatments Record of medical events and side effects of treatments Ra + 13Mo: Final evaluation. Endocrine assessment. 24h Ambulatory BP measurement, anthropometric and metabolic evaluation. Quality of life and cognition questionnaires.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 78 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas
Actual Study Start Date : April 9, 2015
Estimated Primary Completion Date : June 9, 2022
Estimated Study Completion Date : November 9, 2022

Arm Intervention/treatment
Experimental: Surgery followed by intensive medical care
Laparoscopic surgical removal of the adrenal tumor
Procedure: Laparoscopic surgical removal of the adrenal tumor
Active Comparator: Intensive medical treatment only
Standardized medical treatment of hypertension by SAHR.
Drug: Standardized medical treatment of hypertension by SAHR

Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:

  • step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )
  • step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)
  • step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg
  • step 4: Add-on of Indapamide LP 1.5 mg
  • step 5: Add-on of Spironolactone 25 mg
  • step 6: Add-on of Bisoprolol 10 mg
  • step 7: Add-on of Prazosine LP 5mg/day.

Primary Outcome Measures :
  1. Blood pressure value and SAHR step 12 months after inclusion [ Time Frame: 12 months ]
    Treatment response will defined as a reduction of at least 1 step of SAHR at the end of the study, with BP maintained within the study objectives (125-135 mm Hg systolic and 75-85 mm Hg diastolic) according to self-measurement at home.

Secondary Outcome Measures :
  1. Antihypertensive treatment score and daily drug dose [ Time Frame: 12 months ]
  2. Incidence of complications in the two strategies. [ Time Frame: 12 months ]
  3. Direct costs of the two strategies. [ Time Frame: 12 months ]
  4. Assessment of predictive factors for the success of surgery on BP [ Time Frame: 12 months ]
    age, family history of hypertension, duration of hypertension, kidney function, biochemical endocrine abnormalities, urinary steroid profile

  5. number of patients requiring antihypertensive treatment [ Time Frame: 12 months ]
  6. 24 hours ambulatory blood pressure monitoring values [ Time Frame: At inclusion (day 0) and at 12 months ]
  7. Blood glucose and lipid lowering agents values [ Time Frame: 12 months ]
  8. Cardiovascular risk factors/markers level [ Time Frame: 12 months ]
    Comparison of the two therapeutic strategies with regard to cardiovascular risk factors/markers: BMI, body composition evaluated by DEXA, abdominal fat evaluated on CT-scan, fasting blood glucose and insulin, HbA1C, HOMA-IR (homeostasis model of assessment of insulin resistance) and OGTT (oral glucose tolerance test), blood lipids, pro-inflammatory adipokines

  9. Number of patients with persistent diabetes, dyslipidemia and metabolic syndrome [ Time Frame: 12 months ]
  10. Evaluation of quality of life [ Time Frame: At inclusion and 12 months ]
    Comparison of the two therapeutic strategies with regard to quality of life

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≤ 80 years.
  • Incidentally discovered unilateral SCSI:

    • Adrenocortical tumor on CT (spontaneous density < 20 HU and/or relative wash-out > 40%, absolute wash-out > 60% ) and > 2 cm in size.
    • Impaired DST (cortisol > 138 nmol/L or 5 µg/dL)


• Impaired DST (cortisol > 50 83 nmol/L or 1,8 3 µg/dL) AND one biological abnormality of the corticotropic axis at study entry:

  • 8 a.m. plasma ACTH < 2.2 pmol/L (10 pg/ml),
  • In case of ACTH at 8 a.m. between 10 and 20 pg/mL (2.2 and 4.4 pmol/L), peak of ACTH < 30 pg/mL (6.6 pmol/L) after a CRH test
  • midnight cortisol > 150 nmol/L (5.4 µg/dL)
  • elevated late-evening salivary cortisol according to the range of the assay
  • increased 24-hour free urinary cortisol but <2.0-fold the laboratory upper normal limit.
  • Systolic or diastolic hypertension treated


  • Systolic or diastolic hypertension (> 135/85 mmHg) not treated assessed on standard blood pressure self-measurement device.
  • Written informed consent signed by patient and investigator

Exclusion Criteria:

  • Age > 80 years.
  • Bilateral incidentaloma.
  • Incidentally adrenocortical tumor < 2 cm
  • History of myocardial infarction, pulmonary edema or stroke during the previous year
  • Malignant hypertension (> 175-115 mm Hg on self-measurement)
  • Beta-blocker treatment that cannot be suspended.
  • Free urinary cortisol > 2.0-fold upper normal limit
  • 08h00 plasma ACTH concentration > 4.4 pmol/L (20 pg/ml)
  • Chronic renal insufficiency (clearance < 30 mL/min)
  • Exogenous corticosteroid treatment by general or local route (inhaled, eye or ear drops , ophthalmic ointment, topical skin application, ear infiltration) during the 6 months before the trial


• Need for Corticosteroid treatment


• Medication interfering with dexamethasone metabolism.(54)

  • Pregnancy
  • Life-threatening pathology (in the short term)
  • Contra-indications to surgery
  • Lack of control of blood pressure at the end of the Run-In period
  • Dissipation of the biological endocrine criteria for SCSI at the end of the Run-In period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02364089

Show Show 17 study locations
Sponsors and Collaborators
University Hospital, Bordeaux
Layout table for investigator information
Study Chair: Eric FRISON, Doctor University Hospital, Bordeaux
Layout table for additonal information
Responsible Party: University Hospital, Bordeaux
ClinicalTrials.gov Identifier: NCT02364089    
Other Study ID Numbers: CHUBX 2012/34
First Posted: February 16, 2015    Key Record Dates
Last Update Posted: June 9, 2021
Last Verified: June 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Bordeaux:
Adrenal Incidentaloma
Subclinical Cushing's syndrome
Cardiovascular Risk Factors
Metabolic Syndrome
Surgery of adrenal tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Adrenocortical Adenoma
Adrenal Gland Neoplasms
Adrenal Cortex Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Adrenal Cortex Diseases
Adrenal Gland Diseases
Endocrine System Diseases
Epinephryl borate
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Vasoconstrictor Agents